Agenda of the CAT meeting 14-16 February 2024
Submitted by Anonymous (not verified) on 14 February 2024 - 7:51
Agenda of the CAT meeting 14-16 February 2024
EMEA-003144-PIP01-21
Submitted by Anonymous (not verified) on 13 February 2024 - 15:36
EMEA-003144-PIP01-21
EMEA-003125-PIP02-21
Submitted by Anonymous (not verified) on 13 February 2024 - 15:20
EMEA-003125-PIP02-21
Record of data processing activity relating to Security Access Control System (public)
Submitted by Anonymous (not verified) on 13 February 2024 - 14:53
Record of data processing activity relating to Security Access Control System (public)
Agenda of the CVMP meeting 13-15 February 2024
Submitted by Anonymous (not verified) on 13 February 2024 - 12:45
Agenda of the CVMP meeting 13-15 February 2024
HMPC meeting report on European Union herbal monographs, guidelines and other activities - 29-31 January 2024
Submitted by Anonymous (not verified) on 13 February 2024 - 12:30
HMPC meeting report on European Union herbal monographs, guidelines and other activities - 29-31 January 2024
Human medicines European public assessment report (EPAR): Rolufta Ellipta (previously Rolufta), umeclidinium, Date of authorisation: 20/03/2017, Revision: 12, Status: Authorised
Submitted by Anonymous (not verified) on 13 February 2024 - 11:28
Human medicines European public assessment report (EPAR): Rolufta Ellipta (previously Rolufta), umeclidinium, Date of authorisation: 20/03/2017, Revision: 12, Status: Authorised
Scientific recommendations on classification of advanced therapy medicinal products
Submitted by Anonymous (not verified) on 13 February 2024 - 11:27
Scientific recommendations on classification of advanced therapy medicinal products
Human medicines European public assessment report (EPAR): Catiolanze, latanoprost, Date of authorisation: 15/11/2023, Revision: 1, Status: Authorised
Submitted by Anonymous (not verified) on 13 February 2024 - 11:19
Human medicines European public assessment report (EPAR): Catiolanze, latanoprost, Date of authorisation: 15/11/2023, Revision: 1, Status: Authorised
Human medicines European public assessment report (EPAR): Incruse Ellipta (previously Incruse), umeclidinium bromide, Date of authorisation: 28/04/2014, Revision: 19, Status: Authorised
Submitted by Anonymous (not verified) on 13 February 2024 - 11:12
Human medicines European public assessment report (EPAR): Incruse Ellipta (previously Incruse), umeclidinium bromide, Date of authorisation: 28/04/2014, Revision: 19, Status: Authorised